<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/55C268C6-B70B-4CD2-9DA8-F4EE370BCA72"><gtr:id>55C268C6-B70B-4CD2-9DA8-F4EE370BCA72</gtr:id><gtr:name>Shyden Biotechnology Ltd</gtr:name><gtr:address><gtr:line1>53 CAVENDISH ROAD</gtr:line1><gtr:city>BALHAM</gtr:city><gtr:postCode>SW12 0BL</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55C268C6-B70B-4CD2-9DA8-F4EE370BCA72" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>55C268C6-B70B-4CD2-9DA8-F4EE370BCA72</gtr:id><gtr:name>Shyden Biotechnology Ltd</gtr:name><gtr:address><gtr:line1>53 CAVENDISH ROAD</gtr:line1><gtr:city>BALHAM</gtr:city><gtr:postCode>SW12 0BL</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>29998.0</gtr:offerGrant><gtr:projectCost>50038.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D97B2F13-8587-4B95-9659-2A9234CE28ED"><gtr:id>D97B2F13-8587-4B95-9659-2A9234CE28ED</gtr:id><gtr:firstName>Mahendra</gtr:firstName><gtr:surname>Deonarain</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710286"><gtr:id>1AFF8C25-227F-4659-BB4C-29D720E240D7</gtr:id><gtr:title>Allosterically Activated Antibodies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710286</gtr:grantReference><gtr:abstractText>ShyDen Biotechnology is developing a novel antibody format that harnesses the flexibility of
antibodies to bind and ellicit novel functions. The Technology Strategy Board is funding the
development of one of these platforms that has the potential to disrupt the antibody
technology field and lead to a new generation of therapeutic and diagnostic antibodies. Future
antibodies using ShyDen Biotech's new technology promise to be more potent but safer,
exploiting targets previously deemed unsuitable with existing technologies.</gtr:abstractText><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>29998</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710286</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>